APA (7th ed.) Citation

J, R., P, C., M, F., LC, H., M, T., A, S., . . . F, G. (2022). TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Translational lung cancer research, 11(1), 4. https://doi.org/10.21037/tlcr-21-754

Chicago Style (17th ed.) Citation

J, Roeper, Christopoulos P, Falk M, Heukamp LC, Tiemann M, Stenzinger A, Thomas M, and Griesinger F. "TP53 Co-mutations as an Independent Prognostic Factor in 2nd and Further Line Therapy-EGFR Mutated Non-small Cell Lung Cancer IV Patients Treated with Osimertinib." Translational Lung Cancer Research 11, no. 1 (2022): 4. https://doi.org/10.21037/tlcr-21-754.

MLA (9th ed.) Citation

J, Roeper, et al. "TP53 Co-mutations as an Independent Prognostic Factor in 2nd and Further Line Therapy-EGFR Mutated Non-small Cell Lung Cancer IV Patients Treated with Osimertinib." Translational Lung Cancer Research, vol. 11, no. 1, 2022, p. 4, https://doi.org/10.21037/tlcr-21-754.